Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buspirone: future directions

J T Apter1, L A Allen

  • 1Princeton Biomedical Research, PA, New Jersey, USA.

Journal of Clinical Psychopharmacology
|February 6, 1999
PubMed
Summary
This summary is machine-generated.

Buspirone, approved for generalized anxiety disorder (GAD), is being studied for various other conditions. Research suggests potential new therapeutic uses beyond its initial indication.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunotherapy for type 1 diabetes.

British medical bulletin·2021
Same author

Cardiovascular and renal outcomes following percutaneous coronary intervention in a population with renal disease: a case-control study.

QJM : monthly journal of the Association of Physicians·2019
Same author

Spatial location of the space charge effect in individual ion clouds using monodisperse dried microparticulate injection with a twin quadrupole inductively coupled plasma mass spectrometer.

Analytical chemistry·2011
Same author

Eye movements following strychninization of the superior colliculus of cats.

Journal of neurophysiology·2010
Same author

The bacteriology of activated sludge.

The Journal of hygiene·2010
Same author

Effect of continuous aeration on bacterial oxidation of organic matter.

The Journal of hygiene·2010
Same journal

Aripiprazole Withdrawal-Associated Restless Legs Syndrome During Clozapine Treatment in an Adolescent With Schizoaffective Disorder: A Case Report.

Journal of clinical psychopharmacology·2026
Same journal

Salute to Our Reviewers.

Journal of clinical psychopharmacology·2026
Same journal

Article Selected to Receive the Mitchell B. Balter Award for Publications in 2025.

Journal of clinical psychopharmacology·2026
Same journal

Pregnancy Outcomes After First-Trimester Exposure to Vortioxetine: Prospective Outcomes From the MGH National Pregnancy Registry for Psychiatric Medications.

Journal of clinical psychopharmacology·2026
Same journal

Salute to Our Reviewers.

Journal of clinical psychopharmacology·2026
Same journal

Serotonin Syndrome Associated With Polypharmacy in an Elderly Patient With Dementia and Parkinson Disease.

Journal of clinical psychopharmacology·2026
See all related articles

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Medicine

Background:

  • Buspirone was approved by the Food and Drug Administration (FDA) in 1986 for generalized anxiety disorder (GAD).
  • Extensive research has explored buspirone's efficacy and safety across a spectrum of psychiatric and neurological conditions.
  • A growing body of evidence suggests potential applications beyond GAD.

Purpose of the Study:

  • To review the existing body of research on the efficacy and safety of buspirone.
  • To explore emerging and potential new uses for buspirone in various patient populations.
  • To highlight future research directions for buspirone.

Main Methods:

  • Literature review of studies examining buspirone's use.
  • Analysis of placebo-controlled trials and observational studies.

Related Experiment Videos

  • Synthesis of research findings on buspirone's applications in diverse conditions.

    • Main Results:

    • Buspirone has been investigated for panic disorder, major depressive disorder, obsessive-compulsive disorder, and more.
    • Studies also examined its use for behavioral disturbances, dementia, and attention deficit-hyperactivity disorder.
    • Evidence suggests potential benefits for selective serotonin reuptake inhibitor-induced adverse events and tobacco dependence.

    Conclusions:

    • While GAD remains its primary indication, research supports exploring buspirone for other conditions.
    • Further placebo-controlled trials are warranted to confirm efficacy in non-GAD populations.
    • Buspirone shows promise as a versatile therapeutic agent in psychiatry and neurology.